Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 1;27(5):e452-e459.
doi: 10.4317/medoral.25439.

Erythromycin: an alternative for the management of oral mucositis?

D-S Teixeira  1 , G-C Louzeiro, M-A Figueiredo, K Cherubini, F-G Salum
Affiliations
Review

Erythromycin: an alternative for the management of oral mucositis?

D-S Teixeira et al. Med Oral Patol Oral Cir Bucal. .

Abstract

Background: Oral mucositis (OM) is an important acute adverse effect of anticancer therapy. This condition presents high morbidity and may lead to the suspension of anticancer therapy.

Material and methods: We reviewed the literature on the pathobiology of OM and the properties of erythromycin (EM), to consider the possibility of its use for the prevention and treatment of OM. We searched the PubMed, Scopus and Web of Science databases and selected complete articles published in English or Spanish that met the inclusion criteria. The search terms "erythromycin", "inflammation", "immunomodulation" and "oral mucositis" were used.

Results: The control of free radicals, transcription factors and pro-inflammatory cytokines has been considered as the key to the management of OM. EM has the ability to modulate oxidative stress, acts on the transcriptional system and inhibits the production of several cytokines that have been directly implicated in OM pathobiology.

Conclusions: The present review suggests that EM could be effective in the treatment of OM. Experimental studies investigating the use of EM in OM should be encouraged.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The authors declare there is no conflict of interest.

Figures

Figure 1
Figure 1
Model of pathobiology of oral mucositis. Created with BioRender.com.
See this image and copyright information in PMC

References

    1. Campos MI, Campos CN, Aarestrup FM, Aarestrup BJ. Oral mucositis in cancer treatment: Natural history, prevention and treatment. Mol Clin Oncol. 2014;2:337–40. - PMC - PubMed
    1. Villa A, Sonis ST. Mucositis: pathobiology and management. Curr Opin Oncol. 2015;27:159–64. - PubMed
    1. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4:277–84. - PubMed
    1. Ren W, Li XH, Chen BD, Wooley PH. Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-kappaB activity. J Orthop Res. 2004;22:21–9. - PubMed
    1. Uchimura T, Nakamura DS, Link EM, Noguchi Y, Ōmura S, Sunazuka T. Erythromycin acts through the ghrelin receptor to attenuate inflammatory responses in chondrocytes and maintain joint integrity. Biochem Pharmacol. 2019;165:79–90. - PMC - PubMed